All In Biotech

Drug Trial Radar · NCT06656494

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

266

Planned (sponsor's estimate)

Start

Dec 18, 2024

Primary completion

Jun 2027

Study completion Jan 2028

Sponsor

Sponsor type
Industry
First posted
Oct 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

Conditions

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndromes (MDS)

Interventions

  • ICP-248Drug

    Eligible patients will receive ICP-248 orally as per the protocol,once daily for every 28 days as one treatment cycle

  • AzacitidineDrug

    Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol,once daily on days 1-7 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, type, and severity of dose-limiting toxicity (DLT).Time frame: 2.5 years
  2. Recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD).Time frame: 2.5 years
  3. The incidence, nature, and severity of adverse events (AEs) as assessed per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) criteria.Time frame: 2.5 years
  4. AML cohort:Composite complete remission rate by Investigator per ELN 2017 criteria.Time frame: 2.5 years
  5. AML cohort:Composite complete remission rate by completion of cycle 2 by Investigator per ELN 2017 criteria.Time frame: 2.5 years
  6. MDS cohort:mOR rate, including CR, mCR, and PR, assessed by Investigator at any time point during the study per revised IWG 2006 MDS Criteria.Time frame: 2.5 years

Locations

22 sites in 3 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    Orange, California · Recruiting

  • Yale University, Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • H Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • St Vincent's Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Recruiting

  • Anhui Provincial Hospita

    Hefei, Anhui, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Nanfang Hospital Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shengyang, Liaoning, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.